Global pharmaceutical firm Sanofi has joined CMAC – the University of Strathclyde’s internationally leading medicines manufacturing research centre – to advance research and innovation in the sector.

Sanofi joins a consortium of eight Tier 1 partners within the global pharmaceutical industry alongside AstraZeneca, Chiesi, Eli Lilly, Pfizer, Roche, Takeda and UCB.

As a Tier 1 partner, Sanofi gains access to unparalleled resources, including world-class facilities, peer-to-peer knowledge exchange, PhD placements, technical translation pathways, mentorship opportunities, and the ability to shape pioneering research programmes.

The collaboration marks a significant milestone for CMAC in driving collaborative research and innovation within advanced pharmaceutical manufacturing.

Revolutionise medicines

Sanofi’s expertise will further strengthen CMAC’s research portfolio, particularly in accelerating the implementation of CMAC Strategy and its research and translation into industry streams.

The company’s focus on the Digital Transformation of Chemistry, Manufacturing and Controls that are crucial to the development of new therapeutic drugs aligns with CMAC’s vision to revolutionise medicines manufacturing, fostering a sustainable and impactful approach.

Massimo Bresciani, CMAC Industry Director, said: “We are thrilled to welcome Sanofi to our esteemed roster of Tier 1 partners at CMAC. This exciting collaboration underpins our mutual dedication to innovation, propelling us towards a future where collective expertise drives significant industry breakthroughs.”

Robert Yule, Head of US Engineering and Modelling at Sanofi, said: Sanofi looks forward to working with CMAC to advance the use of Digital Twins and promote continuous manufacturing with the goal of producing lower cost drugs that have more eco-friendly manufacturing processes.”

CMAC’s goal is to transform Medicines Development, Manufacture & Supply, and further grow its pipeline of world-class multi-disciplinary collaborative research. The centre’s portfolio currently includes the Made Smarter Innovation: Digital Medicines Manufacturing Research Centre (DM²), EPSRC international Digital Design and Manufacture of Amorphous Pharmaceuticals (DDMAP) collaboration, UKRPIF supported Net Zero Pilot and CMAC Data Lab, and the EPSRC CMAC Future Manufacturing Research Hub, along with training and translation projects within a world-class facility.